In Silico Technologies
A STRATEGIC IMPERATIVE FOR ACCELERATING
BREAKTHROUGHS AND MARKET LEADERSHIP FOR FDA-REGULATED PRODUCTS

In Silico Technologies A STRATEGIC IMPERATIVE FOR ACCELERATING BREAKTHROUGHS AND MARKET LEADERSHIP FOR FDA-REGULATED PRODUCTS

Working with an exceptional team of experts, led by Tina Morrison , over the past month has been an incredible experience for In Silico Technologies discussions. Our mission was clear and impactful: to raise awareness among all stakeholders in the medical product R&D space about the opportunities presented by in silico methods. I strongly encourage all interested parties to explore these methods further. Understanding the significance and benefits of in silico trials can be a game-changer, and adopting these approaches as soon as possible is crucial. Delaying adoption could result in missed opportunities and a strategic disadvantage. Don't be a late adopter; embrace the future of clinical trials now.


Download the report here


Key Points from the Document:

  • Strategic Imperative: ISTs are crucial for breakthroughs and market leadership in FDA-regulated products.
  • Value Proposition:Accelerates innovation and idea exploration.Cost-effective and streamlines knowledge transfer.FDA accepted, supporting regulatory submissions.Enhances product safety and competitive advantage.
  • Drivers for Implementation:Reduces time and cost in preclinical development.Shortens time to market.Reduces or replaces animal testing.Addresses rare condition needs with virtual cohorts.Enhances pre-operative planning efficiency.
  • Economic Considerations:High initial investment but long-term benefits.Significant financial benefits by speeding product delivery.ROI achieved after validation and integration of ISTs.
  • Myths Preventing Implementation:Regulatory acceptance is growing.ISTs offer clear ROI, not just additional cost.Relevant across the product lifecycle.
  • Success Stories:CNS Drug DevelopmentLiver Safety AssessmentTailored Osteotomy for Knee Alignment
  • Resources:Simulation platforms, cloud computing, consultancies, anatomical model software, and government resources support ISTs.
  • Conclusion:ISTs revolutionize development and evaluation of health-related products.Requires cultural shift towards digital transformation.Proactive implementation drives positive outcomes for organizations and patients.

Co-contributors:

Tina M. Morrison

Payman Afshari

Jeff Bischoff

Tejas Canchi, PhD

Luca Emili

Honghui Zhou

Marc Horner, Ph.D.

Nicole Kleinstreuer

Daniel Matlis

Enrique Morales Orcajo, PhD

Mark Palmer, M.D., PhD

April Naab

Greg Paoli

Abhijeet Patil

Ashley Peterson

Raj Vadigepalli

Paul Watkins

Jack Cook

Jesse Fishman


Great to see such clear communication about in silico methods! It’s essential to make these topics accessible for everyone. What specific applications do you find most exciting?

回复
Hadisur Rahman

Founder & HoBD @Devxhub ?? Your Trusted Go-to Team Augmentation & Cost-Effective Software Development Partner. ??Hire Devxhub to make a difference.

9 个月

Luca Emili Clear and concise presentation on in silico methods! Making complex topics accessible is crucial. At Developer eXperience Hub, we excel in web & app development, seamlessly integrating ChatGPT to enhance client websites. Let's innovate together! #InSilicoMethods #WebDevelopment #ChatGPT #DEVxHUB

回复

Well done Luca ! Bravo

回复

要查看或添加评论,请登录

Luca Emili的更多文章

社区洞察

其他会员也浏览了